To study whether the observed sensitivity to MEK/Bcl‐2 inhibition was specific to CLL or a more general feature of B‐cell malignancies, we expanded the study to cell line models of CLL (n = 4), MM (n = 8), and MCL (n = 7). This evidence concerns the gene MAP2K7 and mantle cell lymphoma.